TRIAL OF OPC-41061 FOR TREATMENT OF HYPONATREMIA SECONDARY TO LIVER DISORDER

$0M01FY2000RRNIH

University Of California San Francisco, San Francisco CA

Investigators

Linked publications & trials

Paper 32841311 Paper 30917704 Paper 30635658 Paper 30571226 Paper 29544657 Paper 29479291 Paper 28637271 Paper 28353541 Paper 28296798 Paper 27546606 Paper 27388144 Paper 27382421 Paper 26927006 Paper 26106560 Paper 26091977 Paper 25918834 Paper 25409471 Paper 24959962 Paper 24755714 Paper 24702955 Paper 24683513 Paper 24615880 Paper 24598797 Paper 24570214 Paper 24419071 Paper 24367482 Paper 24260137 Paper 24220913 Paper 24105030 Paper 23954497 Paper 23934991 Paper 23904290 Paper 23901097 Paper 23874208 Paper 23687224 Paper 23649774 Paper 23637325 Paper 23614994 Paper 23508266 Paper 23468661 Paper 23441606 Paper 23441136 Paper 23315317 Paper 23287403 Paper 23249952 Paper 23242158 Paper 23212606 Paper 23175617 Paper 23127215 Paper 23124848 Paper 23073395 Paper 23070669 Paper 23042117 Paper 23023776 Paper 22944874 Paper 22904263 Paper 22863642 Paper 22862153 Paper 22833143 Paper 22707612 Paper 22588883 Paper 22549897 Paper 22523428 Paper 22476155 Paper 22464253 Paper 22436836 Paper 22399793 Paper 22231568 Paper 22189356 Paper 22174698 Paper 22155768 Paper 22110124 Paper 22060063 Paper 22029979 Paper 22027585 Paper 21999979 Paper 21995304 Paper 21991891 Paper 21952918 Paper 21881831 Paper 21875343 Paper 21871250 Paper 21813792 Paper 21768873 Paper 21719445 Paper 21712645 Paper 21637784 Paper 21637766 Paper 21617528 Paper 21614020 Paper 21590681 Paper 21584946 Paper 21512513 Paper 21463066 Paper 21437871 Paper 21430657 Paper 21415358 Paper 21408207 Paper 21391124 Paper 21382963

Abstract

This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of a non-peptide vasopressin (V2) receptor antagonist, OPC-41061, for the treatment of hyponatremia secondary to liver disease. The goal patient enrollment is five patients over a five-month period. The study will be conducted in two phases with an optional third phase: (1) inpatient six-day phase for assessment of baseline characteristics and initiation of therapy, (2)outpatient phase with at least six outpatient evaluations (six anticipated, additional visits may be necessary in the event of a complication), (3) optional 24-hour inpatient evaluation for further pharmacokinetic studies. The GCRC will be used during all phases of evaluation.

View original record on NIH RePORTER →